Identification

Name
Carvedilol
Accession Number
DB01136  (APRD00091)
Type
Small Molecule
Groups
Approved, Investigational
Description

Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-1 adrenergic receptors.

Structure
Thumb
Synonyms
  • (+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol
  • Carvedilol
  • Carvedilolum
  • SKF 105517
Product Ingredients
IngredientUNIICASInChI Key
Carvedilol phosphateEQT531S367610309-89-2LHNYXTULDSJZRB-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-carvedilolTablet12.5 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-carvedilolTablet3.125 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-carvedilolTablet25 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-carvedilolTablet6.25 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Ava-carvedilolTablet3.125 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-carvedilolTablet25 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-carvedilolTablet6.25 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-carvedilolTablet12.5 mgOralAvanstra Inc2011-10-112014-08-21Canada
CarvedilolTablet12.5 mgOralSivem Pharmaceuticals Ulc2004-04-06Not applicableCanada
CarvedilolTablet12.5 mgOralPro Doc Limitee2009-06-12Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-carvedilolTablet6.25 mgOralApotex Corporation2003-08-06Not applicableCanada
Apo-carvedilolTablet12.5 mgOralApotex Corporation2003-08-06Not applicableCanada
Apo-carvedilolTablet3.125 mgOralApotex Corporation2003-08-06Not applicableCanada
Apo-carvedilolTablet25 mgOralApotex Corporation2003-08-06Not applicableCanada
CarvedilolTablet6.25 mg/1OralCipla Limited2007-09-05Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralAphena Pharma Solutions Tennessee, Inc.2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralMylan Institutional2007-09-14Not applicableUs
CarvedilolTablet, film coated6.25 mg/1OralNorthwind Pharmaceuticals2015-02-09Not applicableUs
CarvedilolTablet, film coated25 mg/1OralCadila Pharnmaceuticals2007-09-05Not applicableUs
CarvedilolTablet, film coated3.125 mg/1OralCardinal Health2011-02-18Not applicableUs
International/Other Brands
COREGCR
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Hypertenevide-12.5Carvedilol + L-ArginineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
Categories
UNII
0K47UL67F2
CAS number
72956-09-3
Weight
Average: 406.4742
Monoisotopic: 406.18925733
Chemical Formula
C24H26N2O4
InChI Key
OGHNVEJMJSYVRP-UHFFFAOYSA-N
InChI
InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
IUPAC Name
1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
SMILES
COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2

Pharmacology

Indication

For the treatment of mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin.

Structured Indications
Pharmacodynamics

Carvedilol is a nonselective beta-adrenergic blocking agent with alpha1-blocking activity and is indicated for the treatment of hypertension and mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin. Carvedilol is a racemic mixture in which nonselective b-adrenoreceptor blocking activity is present in the S(-) enantiomer and a-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity. The effect of carvedilol's b-adrenoreceptor blocking activity has been demonstrated in animal and human studies showing that carvedilol (1) reduces cardiac output in normal subjects; (2) reduces exercise-and/or isoproterenol-induced tachycardia and (3) reduces reflex orthostatic tachycardia.

Mechanism of action

Carvedilol is a racemic mixture in which nonselective beta-adrenoreceptor blocking activity is present in the S(-) enantiomer and alpha-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol's beta-adrenergic receptor blocking ability decreases the heart rate, myocardial contractility, and myocardial oxygen demand. Carvedilol also decreases systemic vascular resistance via its alpha adrenergic receptor blocking properties. Carvedilol and its metabolite BM-910228 (a less potent beta blocker, but more potent antioxidant) have been shown to restore the inotropic responsiveness to Ca2+ in OH- free radical-treated myocardium. Carvedilol and its metabolites also prevent OH- radical-induced decrease in sarcoplasmic reticulum Ca2+-ATPase activity. Therefore, carvedilol and its metabolites may be beneficial in chronic heart failure by preventing free radical damage.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
AAlpha-1A adrenergic receptor
antagonist
Human
UNADH dehydrogenase [ubiquinone] 1 subunit C2
inhibitor
Human
UBeta-2 adrenergic receptor
antagonist
Human
UVascular endothelial growth factor A
other
Human
UNatriuretic peptides B
other
Human
UGap junction alpha-1 protein
other
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
UVascular cell adhesion protein 1
inhibitor
Human
UAlpha-1D adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-2C adrenergic receptor
antagonist
Human
UAlpha-2B adrenergic receptor
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
UE-selectin
inhibitor
Human
UHypoxia-inducible factor 1-alpha
modulator
Human
UInward rectifier potassium channel 4Not AvailableHuman
Absorption

Carvedilol is rapidly and extensively absorbed following oral administration, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.

Volume of distribution
  • 115 L
Protein binding

98%

Metabolism

Hepatic. Carvedilol is metabolized primarily by aromatic ring oxidation and glucuronidation. The oxidative metabolites are further metabolized by conjugation via glucuronidation and sulfation. Demethylation and hydroxylation at the phenol ring produce three active metabolites with b-receptor blocking activity. The 4'-hydroxyphenyl metabolite is approximately 13 times more potent than carvedilol for b-blockade.

Route of elimination

Carvedilol is extensively metabolized. Less than 2% of the dose was excreted unchanged in the urine. Carvedilol is metabolized primarily by aromatic ring oxidation and glucuronidation. The oxidative metabolites are further metabolized by conjugation via glucuronidation and sulfation. The metabolites of carvedilol are excreted primarily via the bile into the feces.

Half life

7-10 hours

Clearance
  • 500-700 mL/min
Toxicity

Not expected to be toxic following ingestion.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Carvedilol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Beta-1 adrenergic receptor---(C;C) / (C;G) / (A;A)C Allele, homozygousEffect Directly StudiedPatients with this genotype in ADRB1 have an increased likelihood of responding to carvedilol for the treatment of increased blood pressure.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, increased dizziness.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, increased dizziness.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Carvedilol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Carvedilol.Experimental
AbirateroneThe serum concentration of Carvedilol can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Carvedilol.Approved
AcemetacinAcemetacin may decrease the antihypertensive activities of Carvedilol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Carvedilol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Carvedilol.Approved
AcetohexamideCarvedilol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Acetylcholine.Approved
AcetyldigitoxinCarvedilol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinCarvedilol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Carvedilol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Carvedilol.Approved
AdrafinilCarvedilol may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Carvedilol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Experimental, Investigational
AlaproclateThe serum concentration of Carvedilol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Carvedilol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Carvedilol.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Carvedilol.Experimental
AlfentanilAlfentanil may increase the bradycardic activities of Carvedilol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Carvedilol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Carvedilol is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Carvedilol.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Carvedilol.Experimental
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Carvedilol.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Carvedilol.Approved, Investigational
AmibegronCarvedilol may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineCarvedilol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Carvedilol.Approved
AmiodaroneThe serum concentration of Carvedilol can be increased when it is combined with Amiodarone.Approved, Investigational
AmitrazCarvedilol may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Carvedilol.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Carvedilol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Carvedilol.Approved, Illicit
AmodiaquineThe metabolism of Carvedilol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Carvedilol.Approved, Investigational
AmrinoneCarvedilol may increase the hypotensive activities of Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Carvedilol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Carvedilol.Investigational
AnisodamineCarvedilol may decrease the vasoconstricting activities of Anisodamine.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Carvedilol.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Carvedilol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Carvedilol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Carvedilol.Approved
ApremilastApremilast may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
AprepitantThe serum concentration of Carvedilol can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineCarvedilol may decrease the vasoconstricting activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Arecoline.Experimental
ArformoterolCarvedilol may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Carvedilol.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Carvedilol.Approved, Investigational
ArtemetherThe metabolism of Carvedilol can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Carvedilol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
AtomoxetineThe metabolism of Carvedilol can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Carvedilol.Approved, Investigational
AzapropazoneAzapropazone may decrease the antihypertensive activities of Carvedilol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Carvedilol.Approved
AzelnidipineCarvedilol may increase the hypotensive activities of Azelnidipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Carvedilol is combined with Azilsartan medoxomil.Approved
AzimilideCarvedilol may increase the hypotensive activities of Azimilide.Investigational
AzithromycinThe metabolism of Carvedilol can be decreased when combined with Azithromycin.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Carvedilol.Experimental
BarbitalBarbital may increase the hypotensive activities of Carvedilol.Illicit
BarnidipineCarvedilol may increase the hypotensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Carvedilol.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Carvedilol.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Carvedilol.Approved, Investigational
BencyclaneCarvedilol may increase the hypotensive activities of Bencyclane.Experimental
BendazacBendazac may decrease the antihypertensive activities of Carvedilol.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Carvedilol.Approved
BenidipineCarvedilol may increase the hypotensive activities of Benidipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Carvedilol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Carvedilol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Carvedilol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Illicit
BepridilCarvedilol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantCarvedilol may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Carvedilol.Approved, Vet Approved
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Carvedilol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Carvedilol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Carvedilol.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Carvedilol.Approved, Investigational
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
BitolterolCarvedilol may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BL-1020BL-1020 may increase the hypotensive activities of Carvedilol.Investigational
BoceprevirThe metabolism of Carvedilol can be decreased when combined with Boceprevir.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
BortezomibThe metabolism of Carvedilol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Carvedilol can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Carvedilol.Approved
BQ-123Carvedilol may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Carvedilol.Approved
BretyliumBretylium may increase the bradycardic activities of Carvedilol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Carvedilol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Carvedilol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Carvedilol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Carvedilol.Investigational
BucindololCarvedilol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Carvedilol.Experimental
BufuralolBufuralol may increase the orthostatic hypotensive activities of Carvedilol.Experimental, Investigational
BumadizoneBumadizone may decrease the antihypertensive activities of Carvedilol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Carvedilol.Approved
BunazosinCarvedilol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Carvedilol.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
BupropionThe metabolism of Carvedilol can be decreased when combined with Bupropion.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Carvedilol.Approved
CabergolineCarvedilol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Carvedilol.Experimental
CafedrineCarvedilol may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Carvedilol.Approved
CalfactantCarvedilol may increase the bradycardic activities of Calfactant.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Carvedilol.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Carvedilol is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Carvedilol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Carvedilol.Experimental
CapecitabineThe serum concentration of Carvedilol can be increased when it is combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Carvedilol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Carvedilol is combined with Carbachol.Approved
CarbamazepineThe metabolism of Carvedilol can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Carvedilol.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Carvedilol.Approved
CarboxyamidotriazoleCarvedilol may increase the hypotensive activities of Carboxyamidotriazole.Investigational
CarbutamideCarvedilol may increase the hypoglycemic activities of Carbutamide.Experimental
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Carvedilol.Approved
CaroverineCarvedilol may increase the hypotensive activities of Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Carvedilol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
CastanospermineCastanospermine may decrease the antihypertensive activities of Carvedilol.Experimental
CelecoxibThe metabolism of Carvedilol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CeritinibThe serum concentration of Carvedilol can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Carvedilol.Withdrawn
CevimelineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Carvedilol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carvedilol.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Carvedilol.Experimental
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Carvedilol.Approved, Vet Approved
ChlorpropamideCarvedilol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Carvedilol.Approved
CholecalciferolThe serum concentration of Carvedilol can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Carvedilol.Approved
CicletanineCarvedilol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Carvedilol is combined with Cilazapril.Approved
CilnidipineCarvedilol may increase the hypotensive activities of Cilnidipine.Approved
CimetidineThe serum concentration of Carvedilol can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Carvedilol can be decreased when combined with Cinacalcet.Approved
CinnarizineCarvedilol may increase the hypotensive activities of Cinnarizine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Carvedilol.Approved, Investigational
CirazolineCarvedilol may decrease the vasoconstricting activities of Cirazoline.Experimental
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Carvedilol.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Carvedilol.Approved
ClarithromycinThe metabolism of Carvedilol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Carvedilol can be decreased when combined with Clemastine.Approved
ClenbuterolCarvedilol may decrease the vasoconstricting activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Carvedilol.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Carvedilol.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Carvedilol.Approved, Investigational
ClomipramineThe metabolism of Carvedilol can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Carvedilol.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Carvedilol.Approved, Nutraceutical
CloranololCloranolol may increase the orthostatic hypotensive activities of Carvedilol.Experimental
ClotrimazoleThe serum concentration of Carvedilol can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Carvedilol.Approved
CobicistatThe serum concentration of Carvedilol can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Carvedilol.Approved
CocaineThe metabolism of Carvedilol can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Carvedilol.Approved
ConivaptanThe serum concentration of Carvedilol can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Carvedilol.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Carvedilol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Carvedilol.Vet Approved
CrisaboroleThe serum concentration of Carvedilol can be increased when it is combined with Crisaborole.Approved
CrizotinibThe metabolism of Carvedilol can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Carvedilol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Carvedilol.Investigational
CyclopenthiazideCarvedilol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Carvedilol.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Carvedilol.Approved
CymarinCarvedilol may increase the bradycardic activities of Cymarin.Experimental
Cyproterone acetateThe serum concentration of Carvedilol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Carvedilol.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Carvedilol.Approved
DabrafenibThe serum concentration of Carvedilol can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Carvedilol.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Carvedilol is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Carvedilol.Investigational
DarifenacinThe metabolism of Carvedilol can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineCarvedilol may increase the hypotensive activities of Darodipine.Experimental
DarunavirThe serum concentration of Carvedilol can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Carvedilol can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Carvedilol.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Carvedilol.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Carvedilol.Approved
DeferasiroxThe serum concentration of Carvedilol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilCarvedilol may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Carvedilol can be increased when it is combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Carvedilol.Approved
DeserpidineCarvedilol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Carvedilol.Approved
DesipramineThe metabolism of Carvedilol can be decreased when combined with Desipramine.Approved
DeslanosideCarvedilol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Carvedilol can be increased when it is combined with Desvenlafaxine.Approved
DetomidineCarvedilol may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Carvedilol.Approved, Investigational, Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Carvedilol.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Carvedilol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Carvedilol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Carvedilol is combined with Diclofenamide.Approved
diethylnorspermineCarvedilol may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Carvedilol.Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Carvedilol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Carvedilol.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Carvedilol.Approved
DigoxinDigoxin may increase the bradycardic activities of Carvedilol.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Carvedilol.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Carvedilol.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Carvedilol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Carvedilol is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Carvedilol can be decreased when combined with Diphenhydramine.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Carvedilol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Carvedilol.Approved
DistigmineDistigmine may increase the bradycardic activities of Carvedilol.Experimental
DobutamineCarvedilol may decrease the vasoconstricting activities of Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Carvedilol.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Carvedilol.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Carvedilol.Approved
DopexamineCarvedilol may decrease the vasoconstricting activities of Dopexamine.Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Carvedilol.Approved
DosulepinThe serum concentration of Carvedilol can be increased when it is combined with Dosulepin.Approved
DotarizineCarvedilol may increase the hypotensive activities of Dotarizine.Investigational
DoxazosinCarvedilol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Carvedilol.Approved, Investigational
DoxycyclineThe metabolism of Carvedilol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneDronedarone may increase the bradycardic activities of Carvedilol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Carvedilol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
DuloxetineCarvedilol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Carvedilol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Carvedilol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Carvedilol.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Carvedilol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Carvedilol.Approved
EfavirenzThe serum concentration of Carvedilol can be increased when it is combined with Efavirenz.Approved, Investigational
EfonidipineCarvedilol may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Carvedilol.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Carvedilol.Approved, Investigational
EliglustatThe metabolism of Carvedilol can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Carvedilol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Carvedilol.Approved, Vet Approved
EnalaprilatCarvedilol may increase the hypotensive activities of Enalaprilat.Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Carvedilol.Approved
EndralazineEndralazine may increase the hypotensive activities of Carvedilol.Experimental
EnzalutamideThe serum concentration of Carvedilol can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Carvedilol.Experimental
EperisoneCarvedilol may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Nutraceutical, Withdrawn
EphedrineCarvedilol may decrease the vasoconstricting activities of Ephedrine.Approved
EpibatidineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Epibatidine.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Carvedilol.Approved, Investigational
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Carvedilol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Carvedilol.Approved
EpoprostenolCarvedilol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carvedilol.Approved
Ergoloid mesylateCarvedilol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineCarvedilol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Carvedilol.Approved, Investigational
ErythromycinThe metabolism of Carvedilol can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Carvedilol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Carvedilol.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Carvedilol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Carvedilol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Carvedilol.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Carvedilol.Approved
EtilefrineCarvedilol may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtodolacEtodolac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Carvedilol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
EtoperidoneThe serum concentration of Carvedilol can be increased when it is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Carvedilol.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
EtravirineThe serum concentration of Carvedilol can be increased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Carvedilol.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Carvedilol.Approved
exisulindexisulind may decrease the antihypertensive activities of Carvedilol.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Carvedilol.Approved
FelbinacFelbinac may decrease the antihypertensive activities of Carvedilol.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Carvedilol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Carvedilol.Approved
FendilineCarvedilol may increase the hypotensive activities of Fendiline.Withdrawn
FenoldopamFenoldopam may increase the hypotensive activities of Carvedilol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Carvedilol.Approved
FenoterolCarvedilol may decrease the vasoconstricting activities of Fenoterol.Approved
FentanylFentanyl may increase the bradycardic activities of Carvedilol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Carvedilol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Carvedilol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Carvedilol.Experimental
Ferulic acidCarvedilol may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Carvedilol.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Carvedilol.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Carvedilol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Carvedilol.Approved
FingolimodCarvedilol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Carvedilol.Approved, Withdrawn
FloxuridineThe serum concentration of Carvedilol can be increased when it is combined with Floxuridine.Approved
FluconazoleThe serum concentration of Carvedilol can be increased when it is combined with Fluconazole.Approved
FlunarizineCarvedilol may increase the hypotensive activities of Flunarizine.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Carvedilol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Carvedilol.Experimental
FluorouracilThe serum concentration of Carvedilol can be increased when it is combined with Fluorouracil.Approved
FluoxetineThe metabolism of Carvedilol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Carvedilol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Carvedilol.Approved
FluvastatinThe serum concentration of Carvedilol can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Carvedilol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolCarvedilol may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Carvedilol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Carvedilol can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Carvedilol.Approved
FosphenytoinThe metabolism of Carvedilol can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Carvedilol.Approved, Vet Approved
Fusidic AcidThe serum concentration of Carvedilol can be increased when it is combined with Fusidic Acid.Approved
GabapentinCarvedilol may increase the hypotensive activities of Gabapentin.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Carvedilol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Carvedilol.Approved
GallopamilCarvedilol may increase the hypotensive activities of Gallopamil.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Carvedilol.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Carvedilol.Approved
GemfibrozilThe serum concentration of Carvedilol can be increased when it is combined with Gemfibrozil.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Carvedilol.Approved, Nutraceutical
GitoformateCarvedilol may increase the bradycardic activities of Gitoformate.Experimental
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Carvedilol.Approved
GlibornurideCarvedilol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideCarvedilol may increase the hypoglycemic activities of Gliclazide.Approved
GlipizideCarvedilol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneCarvedilol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideCarvedilol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideCarvedilol may increase the hypoglycemic activities of Glyburide.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Carvedilol.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Carvedilol.Withdrawn
GTS-21The risk or severity of adverse effects can be increased when Carvedilol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Carvedilol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Carvedilol.Approved
GuanazodineCarvedilol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Carvedilol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
GuanoclorCarvedilol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzCarvedilol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanCarvedilol may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Carvedilol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Carvedilol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Carvedilol.Experimental
HexamethoniumCarvedilol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Carvedilol.Approved
HexoprenalineCarvedilol may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineHigenamine may decrease the antihypertensive activities of Carvedilol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Carvedilol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Carvedilol.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carvedilol.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Carvedilol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Carvedilol.Approved
HydroxychloroquineThe metabolism of Carvedilol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Carvedilol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Carvedilol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Carvedilol.Approved
IdelalisibThe serum concentration of Carvedilol can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Carvedilol.Approved, Investigational
ImatinibThe metabolism of Carvedilol can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Carvedilol.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Carvedilol.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Carvedilol.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Carvedilol.Approved
IndalpineThe serum concentration of Carvedilol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Carvedilol.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Carvedilol.Withdrawn
IndinavirThe serum concentration of Carvedilol can be increased when it is combined with Indinavir.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Carvedilol.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Carvedilol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Carvedilol.Withdrawn
IndoraminCarvedilol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Carvedilol.Approved
Insulin PorkCarvedilol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Carvedilol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Carvedilol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Carvedilol.Withdrawn
IrbesartanThe serum concentration of Carvedilol can be increased when it is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Carvedilol.Approved, Investigational
IsavuconazoniumThe metabolism of Carvedilol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Carvedilol.Approved
IsoetarineCarvedilol may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Carvedilol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Carvedilol.Approved, Withdrawn
IsoniazidThe metabolism of Carvedilol can be decreased when combined with Isoniazid.Approved
IsoprenalineCarvedilol may decrease the vasoconstricting activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Carvedilol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Carvedilol.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Carvedilol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Carvedilol.Approved
ItraconazoleThe metabolism of Carvedilol can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineCarvedilol may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Carvedilol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Carvedilol.Approved, Vet Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Carvedilol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Carvedilol.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Carvedilol.Approved
KetoconazoleThe serum concentration of Carvedilol can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Carvedilol.Approved
LabetalolLabetalol may increase the orthostatic hypotensive activities of Carvedilol.Approved
LacidipineCarvedilol may increase the hypotensive activities of Lacidipine.Approved
LacosamideCarvedilol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Carvedilol.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Carvedilol.Approved, Investigational
Lanatoside CCarvedilol may increase the bradycardic activities of Lanatoside C.Experimental
LandiololLandiolol may increase the orthostatic hypotensive activities of Carvedilol.Investigational
LanreotideCarvedilol may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Carvedilol.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Carvedilol.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Carvedilol.Approved
LeflunomideThe serum concentration of Carvedilol can be increased when it is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Carvedilol.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Carvedilol.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Carvedilol.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Carvedilol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Carvedilol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Carvedilol.Approved
LevodopaCarvedilol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Carvedilol.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Carvedilol.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Carvedilol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Carvedilol.Approved, Vet Approved
LidoflazineCarvedilol may increase the hypotensive activities of Lidoflazine.Experimental
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Carvedilol.Approved
LinsidomineCarvedilol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Carvedilol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Carvedilol.Investigational
LobeglitazoneThe serum concentration of Carvedilol can be increased when it is combined with Lobeglitazone.Approved
LobelineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Carvedilol.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Carvedilol.Approved
LopinavirThe metabolism of Carvedilol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Carvedilol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Carvedilol.Approved
LosartanThe serum concentration of Carvedilol can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Carvedilol can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Carvedilol.Approved
LucinactantCarvedilol may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Carvedilol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Carvedilol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Carvedilol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
MacitentanCarvedilol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Carvedilol.Approved
Magnesium SulfateCarvedilol may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
MalathionMalathion may increase the bradycardic activities of Carvedilol.Approved, Investigational
ManidipineThe serum concentration of Carvedilol can be increased when it is combined with Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Carvedilol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Carvedilol.Approved
MebanazineMebanazine may increase the hypotensive activities of Carvedilol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Carvedilol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
MedetomidineCarvedilol may decrease the vasoconstricting activities of Medetomidine.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Carvedilol.Approved
MefloquineMefloquine may increase the bradycardic activities of Carvedilol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Carvedilol.Approved, Investigational
MephentermineCarvedilol may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Carvedilol.Experimental
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Carvedilol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Carvedilol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Carvedilol.Approved
MetahexamideCarvedilol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Carvedilol.Withdrawn
MetaraminolCarvedilol may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethacholineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Methacholine.Approved
MethadoneThe metabolism of Carvedilol can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Carvedilol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Carvedilol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Carvedilol.Approved
MethoserpidineCarvedilol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Carvedilol.Approved
MethotrimeprazineThe metabolism of Carvedilol can be decreased when combined with Methotrimeprazine.Approved
MethoxamineCarvedilol may decrease the vasoconstricting activities of Methoxamine.Approved
MethoxyphenamineCarvedilol may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carvedilol.Approved
Methyl salicylateMethyl salicylate may increase the bradycardic activities of Carvedilol.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Carvedilol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Carvedilol.Investigational
MethylergometrineCarvedilol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Carvedilol.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Carvedilol.Approved, Vet Approved
MetildigoxinCarvedilol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Carvedilol is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Carvedilol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Carvedilol.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
MetyrosineCarvedilol may increase the hypotensive activities of Metyrosine.Approved
MexiletineThe metabolism of Carvedilol can be decreased when combined with Mexiletine.Approved
MibefradilCarvedilol may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Carvedilol.Approved, Illicit
MidodrineCarvedilol may increase the bradycardic activities of Midodrine.Approved
MidostaurinThe serum concentration of Carvedilol can be increased when it is combined with Midostaurin.Approved
MifepristoneThe serum concentration of Carvedilol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Carvedilol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Carvedilol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Carvedilol.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Carvedilol.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Carvedilol.Investigational
MitotaneThe serum concentration of Carvedilol can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Carvedilol.Approved, Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Carvedilol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Carvedilol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Carvedilol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Carvedilol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Carvedilol.Approved
MoricizineMoricizine may increase the hypotensive activities of Carvedilol.Approved, Withdrawn
MorphineThe serum concentration of Morphine can be increased when it is combined with Carvedilol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
MuzolimineCarvedilol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Carvedilol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Carvedilol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Carvedilol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Carvedilol.Approved
NadololNadolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Carvedilol.Approved
NaftopidilCarvedilol may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Carvedilol.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Carvedilol.Approved, Vet Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Carvedilol is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Carvedilol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Carvedilol can be decreased when combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Carvedilol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Carvedilol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Carvedilol is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Carvedilol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Carvedilol can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Carvedilol.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Carvedilol.Approved
NicorandilNicorandil may increase the hypotensive activities of Carvedilol.Approved
NicotineThe metabolism of Carvedilol can be decreased when combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Carvedilol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Carvedilol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Carvedilol.Approved
NiguldipineCarvedilol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Carvedilol can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineCarvedilol may increase the hypotensive activities of Niludipine.Experimental
NilvadipineCarvedilol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideCarvedilol may increase the hypotensive activities of Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Carvedilol.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Carvedilol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Carvedilol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Carvedilol.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Carvedilol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Carvedilol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Carvedilol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Carvedilol.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Carvedilol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
NorfenefrineCarvedilol may decrease the vasoconstricting activities of Norfenefrine.Experimental
NylidrinCarvedilol may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabCarvedilol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Carvedilol.Withdrawn
OctopamineCarvedilol may decrease the vasoconstricting activities of Octopamine.Experimental
OctreotideOctreotide may increase the bradycardic activities of Carvedilol.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Carvedilol.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Carvedilol.Approved, Investigational
OlaparibThe metabolism of Carvedilol can be decreased when combined with Olaparib.Approved
OleandrinCarvedilol may increase the bradycardic activities of Oleandrin.Experimental
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carvedilol.Approved, Investigational
OlodaterolCarvedilol may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Carvedilol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Carvedilol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Carvedilol.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Carvedilol.Approved
OmeprazoleThe serum concentration of Carvedilol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalineCarvedilol may decrease the vasoconstricting activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Carvedilol.Vet Approved
OsimertinibThe serum concentration of Carvedilol can be increased when it is combined with Osimertinib.Approved
OtiloniumCarvedilol may increase the hypotensive activities of Otilonium.Experimental
OuabainCarvedilol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Carvedilol.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
OxyfedrineCarvedilol may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Carvedilol.Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Carvedilol.Approved, Vet Approved
PalbociclibThe serum concentration of Carvedilol can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
PanobinostatThe serum concentration of Carvedilol can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Carvedilol.Approved
ParaoxonParaoxon may increase the bradycardic activities of Carvedilol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Carvedilol.Approved
PargylinePargyline may increase the hypotensive activities of Carvedilol.Approved
ParoxetineThe metabolism of Carvedilol can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Carvedilol.Investigational
PasireotideCarvedilol may increase the bradycardic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Carvedilol.Approved
Peginterferon alfa-2bThe serum concentration of Carvedilol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
PentobarbitalThe metabolism of Carvedilol can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Carvedilol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Carvedilol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Carvedilol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Vet Approved, Withdrawn
PerhexilineCarvedilol may increase the hypotensive activities of Perhexiline.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Carvedilol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Carvedilol.Approved
PeruvosideCarvedilol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Carvedilol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Carvedilol.Withdrawn
PhenobarbitalThe metabolism of Carvedilol can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Carvedilol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Carvedilol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Carvedilol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
PhenylephrineCarvedilol may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Carvedilol can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Carvedilol.Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Carvedilol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Carvedilol.Withdrawn
PinaveriumCarvedilol may increase the hypotensive activities of Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Carvedilol.Approved
PirbuterolCarvedilol may decrease the vasoconstricting activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Carvedilol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Carvedilol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Carvedilol.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Carvedilol.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Carvedilol.Withdrawn
PolythiazideCarvedilol may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Carvedilol.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Carvedilol.Approved
Poractant alfaCarvedilol may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Carvedilol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Carvedilol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Carvedilol.Experimental
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Carvedilol.Approved
PrazosinCarvedilol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Carvedilol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Carvedilol.Approved, Vet Approved
PregabalinCarvedilol may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenalterolCarvedilol may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineCarvedilol may increase the hypotensive activities of Prenylamine.Withdrawn
PrimaquineThe metabolism of Carvedilol can be decreased when combined with Primaquine.Approved
PrimidoneThe metabolism of Carvedilol can be increased when combined with Primidone.Approved, Vet Approved
ProcaterolCarvedilol may decrease the vasoconstricting activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Carvedilol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Carvedilol.Experimental
PromazineThe metabolism of Carvedilol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Carvedilol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Carvedilol.Approved
PropafenoneThe serum concentration of Carvedilol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Carvedilol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Carvedilol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Carvedilol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Carvedilol.Experimental
ProscillaridinCarvedilol may increase the bradycardic activities of Proscillaridin.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Carvedilol.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Carvedilol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Carvedilol.Approved
PyrimethamineThe serum concentration of Carvedilol can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Carvedilol.Approved, Investigational
QuinidineThe metabolism of Carvedilol can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Carvedilol can be increased when it is combined with Quinine.Approved
RacepinephrineCarvedilol may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineCarvedilol may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Carvedilol.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Carvedilol.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Carvedilol.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Carvedilol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Carvedilol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carvedilol.Approved
RemikirenRemikiren may increase the hypotensive activities of Carvedilol.Approved
ReproterolCarvedilol may decrease the vasoconstricting activities of Reproterol.Investigational
RescinnamineCarvedilol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Carvedilol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Carvedilol.Experimental, Investigational
RifabutinThe metabolism of Carvedilol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Carvedilol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Carvedilol can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Carvedilol.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Carvedilol.Investigational
RimiterolCarvedilol may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatThe risk or severity of adverse effects can be increased when Carvedilol is combined with Riociguat.Approved
RisedronateCarvedilol may increase the hypotensive activities of Risedronate.Approved, Investigational
RisperidoneCarvedilol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronCarvedilol may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineCarvedilol may decrease the vasoconstricting activities of Ritodrine.Approved
RitonavirThe metabolism of Carvedilol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabCarvedilol may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Carvedilol.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Carvedilol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Carvedilol.Investigational, Withdrawn
RolapitantThe metabolism of Carvedilol can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Carvedilol.Approved, Investigational
RomifidineCarvedilol may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carvedilol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Carvedilol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Carvedilol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Carvedilol.Approved
SafrazineSafrazine may increase the hypotensive activities of Carvedilol.Withdrawn
SalbutamolCarvedilol may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Carvedilol.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Carvedilol.Approved, Vet Approved
SalmeterolCarvedilol may decrease the vasoconstricting activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Carvedilol.Approved
SaprisartanCarvedilol may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Carvedilol can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Carvedilol can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Carvedilol.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Carvedilol.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Carvedilol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Carvedilol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Carvedilol.Investigational
SertralineThe metabolism of Carvedilol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carvedilol.Approved, Vet Approved
SildenafilThe serum concentration of Carvedilol can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Carvedilol.Approved
SiltuximabThe serum concentration of Carvedilol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Carvedilol can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Carvedilol.Approved, Investigational
SitaxentanCarvedilol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Carvedilol.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Carvedilol.Approved
SolabegronCarvedilol may decrease the vasoconstricting activities of Solabegron.Investigational
SorafenibThe serum concentration of Carvedilol can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Carvedilol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Carvedilol.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Carvedilol.Experimental
SpiraprilCarvedilol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Carvedilol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Carvedilol.Investigational
St. John's WortThe serum concentration of Carvedilol can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Carvedilol can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Carvedilol.Approved
SufentanilSufentanil may increase the bradycardic activities of Carvedilol.Approved, Investigational
SulfadiazineThe serum concentration of Carvedilol can be increased when it is combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Carvedilol can be increased when it is combined with Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Carvedilol.Approved
SulfisoxazoleThe serum concentration of Carvedilol can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Carvedilol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Carvedilol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Carvedilol.Experimental
SynephrineCarvedilol may decrease the vasoconstricting activities of Synephrine.Experimental
TacrineTacrine may increase the bradycardic activities of Carvedilol.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Carvedilol.Approved, Investigational
TadalafilTadalafil may increase the hypotensive activities of Carvedilol.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Carvedilol.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Carvedilol.Approved
TamsulosinCarvedilol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Carvedilol.Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Carvedilol.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Carvedilol.Approved
TelaprevirThe metabolism of Carvedilol can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Carvedilol can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carvedilol.Approved, Investigational
TemocaprilCarvedilol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Carvedilol.Approved
TenidapTenidap may decrease the antihypertensive activities of Carvedilol.Experimental
Tenofovir disoproxilThe metabolism of Carvedilol can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Carvedilol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Carvedilol.Vet Approved
TerazosinCarvedilol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Carvedilol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineCarvedilol may decrease the vasoconstricting activities of Terbutaline.Approved
TeriflunomideThe serum concentration of Carvedilol can be decreased when it is combined with Teriflunomide.Approved
TerlipressinCarvedilol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerodilineCarvedilol may increase the hypotensive activities of Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Carvedilol.Experimental
TetrahydropalmatineCarvedilol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Carvedilol.Approved, Investigational, Withdrawn
TheodrenalineCarvedilol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Carvedilol can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Carvedilol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Carvedilol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
ThioridazineThe metabolism of Carvedilol can be decreased when combined with Thioridazine.Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Carvedilol.Approved
TiboloneCarvedilol may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Carvedilol can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Carvedilol can be increased when it is combined with Ticlopidine.Approved
TicrynafenCarvedilol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Carvedilol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Carvedilol.Investigational
TipranavirThe metabolism of Carvedilol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
TocilizumabThe serum concentration of Carvedilol can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Carvedilol.Approved, Investigational
TolazamideCarvedilol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
TolbutamideThe serum concentration of Carvedilol can be increased when it is combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carvedilol.Approved, Withdrawn
Tolfenamic AcidCarvedilol may increase the hypotensive activities of Tolfenamic Acid.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Carvedilol.Approved
TolonidineCarvedilol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Carvedilol.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Carvedilol.Approved
TopiroxostatThe serum concentration of Carvedilol can be increased when it is combined with Topiroxostat.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Carvedilol.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Carvedilol.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Carvedilol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Carvedilol.Approved
TranilastCarvedilol may increase the hypotensive activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Carvedilol.Experimental
TranylcypromineThe metabolism of Carvedilol can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Carvedilol.Approved
TravoprostTravoprost may increase the hypotensive activities of Carvedilol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Carvedilol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Carvedilol.Approved, Investigational, Nutraceutical
TretoquinolCarvedilol may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Carvedilol.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Carvedilol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Carvedilol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Carvedilol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Carvedilol.Approved, Vet Approved
TrimazosinCarvedilol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Carvedilol.Approved
TrimethoprimThe serum concentration of Carvedilol can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TriptolideTriptolide may decrease the antihypertensive activities of Carvedilol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Carvedilol.Approved
TulobuterolCarvedilol may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Carvedilol.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Carvedilol.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Carvedilol.Approved
UnoprostoneCarvedilol may increase the hypotensive activities of Unoprostone.Approved
UrapidilCarvedilol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Carvedilol.Investigational, Withdrawn
Valproic AcidThe serum concentration of Carvedilol can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe serum concentration of Carvedilol can be increased when it is combined with Valsartan.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Carvedilol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Carvedilol is combined with Varenicline.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Carvedilol.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Carvedilol.Approved
VemurafenibThe serum concentration of Carvedilol can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Carvedilol.Approved
VenlafaxineThe metabolism of Carvedilol can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Carvedilol.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Carvedilol.Approved
VincamineCarvedilol may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Carvedilol.Approved, Investigational
VinpocetineCarvedilol may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Carvedilol.Approved
VoriconazoleThe serum concentration of Carvedilol can be increased when it is combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Carvedilol.Approved
XamoterolCarvedilol may decrease the vasoconstricting activities of Xamoterol.Experimental
XipamideCarvedilol may increase the hypotensive activities of Xipamide.Experimental
XylazineCarvedilol may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved
YM-178Carvedilol may decrease the vasoconstricting activities of YM-178.Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Carvedilol.Approved, Vet Approved
ZafirlukastThe serum concentration of Carvedilol can be increased when it is combined with Zafirlukast.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Carvedilol.Approved
ZiconotideCarvedilol may increase the hypotensive activities of Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Carvedilol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Carvedilol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Carvedilol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Carvedilol can be decreased when combined with Ziprasidone.Approved
ZofenoprilCarvedilol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Carvedilol.Withdrawn
ZucapsaicinThe metabolism of Carvedilol can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Take with food, food slows the absorption rate and reduces the incidence of adverse effects (extent of absorption is not affected).

References

Synthesis Reference

Ilan Kor, "Crystalline solids of carvedilol and processes for their preparation." U.S. Patent US20030166702, issued September 04, 2003.

US20030166702
General References
  1. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002 Oct 22;106(17):2194-9. [PubMed:12390947]
  2. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651-8. [PubMed:11386263]
  3. Vanderhoff BT, Ruppel HM, Amsterdam PB: Carvedilol: the new role of beta blockers in congestive heart failure. Am Fam Physician. 1998 Nov 1;58(7):1627-34, 1641-2. [PubMed:9824960]
External Links
Human Metabolome Database
HMDB15267
KEGG Drug
D00255
KEGG Compound
C06875
PubChem Compound
2585
PubChem Substance
46505146
ChemSpider
2487
BindingDB
25759
ChEBI
3441
ChEMBL
CHEMBL723
Therapeutic Targets Database
DAP000135
PharmGKB
PA448817
IUPHAR
551
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Carvedilol
ATC Codes
C07AG02 — Carvedilol
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
FDA label
Download (1.25 MB)
MSDS
Download (32.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers6
1CompletedDiagnosticHeart Diseases1
1CompletedPreventionHypertensive1
1CompletedTreatmentChronic Heart Failure (CHF) / Congestive Heart Failure (CHF)1
1CompletedTreatmentFasting State1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentHypertensive3
1WithdrawnTreatmentPulmonary Hypertension (PH)1
1, 2CompletedTreatmentPre-Hypertension1
1, 2CompletedTreatmentPulmonary Arterial Hypertension (PAH)1
1, 2RecruitingNot AvailableCoronary Microvascular Disease1
1, 2WithdrawnTreatmentPulmonary Arterial Hypertension (PAH)1
2Active Not RecruitingPreventionCancer, Breast1
2Active Not RecruitingSupportive CareCancer Survivors1
2Active Not RecruitingSupportive CareCancer, Breast / Cardiac Toxicity1
2CompletedTreatmentCardiac MRI <40 / Pulmonary Hypertension (PH)1
2CompletedTreatmentCocaine Withdrawal / Dependence, Cocaine1
2CompletedTreatmentCocaine-Related Disorders1
2Not Yet RecruitingTreatmentProstate Cancer1
2RecruitingPreventionCancer Survivors / Heart Failure, Unspecified1
2RecruitingPreventionCardiovascular Abnormalities / HER2 Positive Breast Cancers1
2RecruitingPreventionCardiovascular Disease (CVD) / Diabetes / Hypertensive1
2RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
2RecruitingTreatmentSmoking1
2TerminatedTreatmentHypertensive1
2Unknown StatusTreatmentPost-Traumatic Stress Disorder (PTSD)1
2WithdrawnNot AvailableFeeling Anxious / Relapses / Substance Addiction1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedPreventionAutologous Hematopoietic Stem Cell Transplantation / Leukemia Acute Myeloid Leukemia (AML) / Lymphoid Neoplasms / Malignant Lymphomas / Multiple Myeloma (MM) / Precursor-cell Lymphoblastic Leukemia-Lymphoma1
3CompletedPreventionLiver Cirrhosis / Portal Hypertension1
3CompletedTreatmentChronic Heart Failure (CHF)1
3CompletedTreatmentCongestive Heart Failure (CHF)3
3CompletedTreatmentHeart Failure, Unspecified1
3CompletedTreatmentHypertensive1
3CompletedTreatmentHypertensive / Obesity, Abdominal1
3CompletedTreatmentNonvalvular Atrial Fibrillation2
3RecruitingPreventionCancer, Breast / Cardiotoxicity / Heart Failure, Unspecified1
3RecruitingTreatmentPortal Hypertension1
3TerminatedTreatmentHeart Failure, Unspecified / Nonvalvular Atrial Fibrillation1
3Unknown StatusTreatmentHypertension,Essential1
3WithdrawnTreatmentPortal Hypertension Related to Cirrhosis1
4CompletedBasic ScienceIdiopathic Dilated Cardiomyopathy1
4CompletedDiagnosticDiabetes1
4CompletedDiagnosticHeart Failure, Unspecified / Prophylaxis of cardiomyopathy1
4CompletedPreventionAscites / Hepatic Encephalopathy / Portal Hypertension Gastropathy / Spontaneous Bacterial Peritonitis (SBP) / Varices, Esophageal1
4CompletedPreventionHypertensive / Type 2 Diabetes Mellitus1
4CompletedPreventionVariceal Rebleeding1
4CompletedTreatmentAltitude / Arterial hypoxia / Heart Failure, Unspecified1
4CompletedTreatmentAlzheimer's Disease (AD)1
4CompletedTreatmentChronic Heart Failure (CHF)1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentCoronary Artery Disease / Hypertensive1
4CompletedTreatmentHeart Failure, Unspecified / Ventricular Dysfunction, Left1
4CompletedTreatmentHypertensive5
4CompletedTreatmentIntradialytic Hypertension1
4CompletedTreatmentMyocardial Infarction (MI)1
4CompletedTreatmentChronic, stable Angina pectoris1
4Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation1
4Not Yet RecruitingTreatmentPortal Hypertension1
4RecruitingBasic ScienceAcute Coronary Syndromes (ACS)1
4RecruitingPreventionEsophageal and Gastric Varices / Hemorrhage / Liver Cirrhosis1
4RecruitingPreventionGastroesophageal Varices / Liver Cirrhosis1
4RecruitingPreventionLiver Cirrhosis / Portal Hypertension1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4RecruitingTreatmentEsophageal and Gastric Varices1
4RecruitingTreatmentEsophageal and Gastric Varices / Liver Cirrhosis1
4RecruitingTreatmentFontan / Univentricular heart1
4RecruitingTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
4RecruitingTreatmentHypertensive1
4RecruitingTreatmentLiver Cirrhosis / Portal Hypertension1
4TerminatedTreatmentHeart Failure, Unspecified1
4Unknown StatusNot AvailableDiabetes Mellitus (DM) / Endothelial Function / Hypertensive1
4Unknown StatusPreventionBecker's Muscular Dystrophy (BMD) / Duchenne's Muscular Dystrophy (DMD)1
4Unknown StatusPreventionDuchenne's Muscular Dystrophy (DMD) / Prophylaxis of cardiomyopathy1
4Unknown StatusPreventionPortal Hypertension1
4Unknown StatusPreventionVariceal Bleeding1
4Unknown StatusTreatmentAnginal Pain / Coronary Heart Disease (CHD) / Hemodialysis-dependent patients1
4Unknown StatusTreatmentCongestive Cardiomyopathy1
4Unknown StatusTreatmentHypertensive1
4Unknown StatusTreatmentHypertensive / Type 2 Diabetes Mellitus1
4WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD) / Heart Failure, Unspecified1
Not AvailableActive Not RecruitingTreatmentHeart Failure, Unspecified1
Not AvailableCompletedNot AvailableAcute Myocardial Infarction (AMI) / Heart Failure, Unspecified1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableHypertensive1
Not AvailableCompletedBasic ScienceAmphetamine-Related Disorders / Moods Disorders / Substance-Related Disorders1
Not AvailableCompletedHealth Services ResearchDependence, Cocaine / Opiate Dependence1
Not AvailableCompletedPreventionDiabetes / Hypertensive1
Not AvailableCompletedPreventionLiver Cirrhosis1
Not AvailableCompletedTreatmentArrythmias / Nonvalvular Atrial Fibrillation1
Not AvailableCompletedTreatmentChronic Liver Diseases (CLD) / Diastolic Dysfunction1
Not AvailableCompletedTreatmentPulmonary Hypertension (PH)1
Not AvailableNot Yet RecruitingNot AvailableLiver Cirrhosis / Portal Hypertension1
Not AvailableRecruitingNot AvailableLiver Cirrhosis / Portal Hypertension / Varix, Esophageal1
Not AvailableRecruitingPreventionLiver Cirrhosis1
Not AvailableRecruitingTreatmentAcute on Chronic Liver Failure1
Not AvailableRecruitingTreatmentCirrhosis With Esophageal Varices / Cirrhosis With Large Esophageal Varices1
Not AvailableRecruitingTreatmentHepatocellular Carcinoma With Portal Vein Thrombosis1
Not AvailableRecruitingTreatmentHypertensive1
Not AvailableRecruitingTreatmentLiver Cirrhosis1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableUnknown StatusNot AvailableHeart Failure, Unspecified1
Not AvailableUnknown StatusTreatmentChronic Heart Failure (CHF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral12.5 mg/1
TabletOral25 mg/1
TabletOral25.0 mg
TabletOral3.125 mg/1
TabletOral6.25 mg/1
Tablet, film coatedOral12.5 mg/301
Tablet, film coatedOral12.5 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral3.125 mg/1
Tablet, film coatedOral6.25 mg/1
Capsule, extended releaseOral10 mg/1
Capsule, extended releaseOral20 mg/1
Capsule, extended releaseOral40 mg/1
Capsule, extended releaseOral80 mg/1
TabletOral50 mg
Kit
TabletOral12.5 mg
TabletOral25 mg
TabletOral3.125 mg
TabletOral6.25 mg
Prices
Unit descriptionCostUnit
Coreg CR 10 mg 24 Hour Capsule4.77USD capsule
Coreg CR 20 mg 24 Hour Capsule4.77USD capsule
Coreg CR 40 mg 24 Hour Capsule4.77USD capsule
Coreg CR 80 mg 24 Hour Capsule4.77USD capsule
Coreg cr 10 mg capsule4.59USD capsule
Coreg cr 20 mg capsule4.59USD capsule
Coreg cr 40 mg capsule4.59USD capsule
Coreg cr 80 mg capsule4.59USD capsule
Coreg 12.5 mg tablet2.54USD tablet
Coreg 25 mg tablet2.54USD tablet
Coreg 3.125 mg tablet2.54USD tablet
Coreg 6.25 mg tablet2.54USD tablet
Carvedilol 12.5 mg tablet2.18USD tablet
Carvedilol 25 mg tablet2.18USD tablet
Carvedilol 3.125 mg tablet2.18USD tablet
Carvedilol 6.25 mg tablet2.18USD tablet
Apo-Carvedilol 12.5 mg Tablet0.84USD tablet
Apo-Carvedilol 25 mg Tablet0.84USD tablet
Apo-Carvedilol 3.125 mg Tablet0.84USD tablet
Apo-Carvedilol 6.25 mg Tablet0.84USD tablet
Phl-Carvedilol 12.5 mg Tablet0.79USD tablet
Phl-Carvedilol 3.125 mg Tablet0.79USD tablet
Phl-Carvedilol 6.25 mg Tablet0.79USD tablet
Pms-Carvedilol 12.5 mg Tablet0.79USD tablet
Pms-Carvedilol 25 mg Tablet0.79USD tablet
Pms-Carvedilol 3.125 mg Tablet0.79USD tablet
Pms-Carvedilol 6.25 mg Tablet0.79USD tablet
Ran-Carvedilol 12.5 mg Tablet0.79USD tablet
Ran-Carvedilol 25 mg Tablet0.79USD tablet
Ran-Carvedilol 3.125 mg Tablet0.79USD tablet
Ran-Carvedilol 6.25 mg Tablet0.79USD tablet
Ratio-Carvedilol 12.5 mg Tablet0.79USD tablet
Ratio-Carvedilol 25 mg Tablet0.79USD tablet
Ratio-Carvedilol 3.125 mg Tablet0.79USD tablet
Ratio-Carvedilol 6.25 mg Tablet0.79USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7268156Yes2003-12-272023-12-27Us
US8101209Yes2006-03-112026-03-11Us
US6022562Yes1996-04-172016-04-17Us
USRE40000Yes1995-12-072015-12-07Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)114.5 °CPhysProp
water solubilityPractically insoluble (0.583 mg/L)Not Available
logP4.19AVDEEF,A (1997)
Predicted Properties
PropertyValueSource
Water Solubility0.00444 mg/mLALOGPS
logP3.05ALOGPS
logP3.42ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)14.03ChemAxon
pKa (Strongest Basic)8.74ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area75.74 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.64 m3·mol-1ChemAxon
Polarizability45.03 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9706
Blood Brain Barrier-0.6814
Caco-2 permeable-0.6308
P-glycoprotein substrateSubstrate0.8552
P-glycoprotein inhibitor INon-inhibitor0.8729
P-glycoprotein inhibitor IINon-inhibitor0.6521
Renal organic cation transporterNon-inhibitor0.5405
CYP450 2C9 substrateNon-substrate0.7517
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5408
CYP450 1A2 substrateInhibitor0.524
CYP450 2C9 inhibitorNon-inhibitor0.8496
CYP450 2D6 inhibitorNon-inhibitor0.7274
CYP450 2C19 inhibitorNon-inhibitor0.5676
CYP450 3A4 inhibitorNon-inhibitor0.6352
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6048
Ames testNon AMES toxic0.8261
CarcinogenicityNon-carcinogens0.9692
BiodegradationNot ready biodegradable0.963
Rat acute toxicity2.4566 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5725
hERG inhibition (predictor II)Inhibitor0.8889
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-1662900000-f901a62f255da92e9a09
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0220900000-5821022307fc5077033b

Taxonomy

Description
This compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Carbazoles
Direct Parent
Carbazoles
Alternative Parents
Indoles / Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / Pyrroles / Heteroaromatic compounds / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines
show 3 more
Substituents
Carbazole / Indole / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Monocyclic benzene moiety / Benzenoid / Pyrrole
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
secondary alcohol, secondary amino compound, carbazoles (CHEBI:3441)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Nichols AJ, Gellai M, Ruffolo RR Jr: Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol. 1991;5(1):25-38. [PubMed:1712335]
  2. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr: In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology. 1989;39(5):327-36. [PubMed:2575762]
  3. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr: The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors. Chirality. 1989;1(4):265-70. [PubMed:2577144]
  4. de Mey C, Breithaupt K, Schloos J, Neugebauer G, Palm D, Belz GG: Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans. Clin Pharmacol Ther. 1994 Mar;55(3):329-37. [PubMed:7908256]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Nadh dehydrogenase (ubiquinone) activity
Specific Function
Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons ...
Gene Name
NDUFC2
Uniprot ID
O95298
Uniprot Name
NADH dehydrogenase [ubiquinone] 1 subunit C2
Molecular Weight
14187.33 Da
References
  1. Oliveira PJ, Santos DJ, Moreno AJ: Carvedilol inhibits the exogenous NADH dehydrogenase in rat heart mitochondria. Arch Biochem Biophys. 2000 Feb 15;374(2):279-85. [PubMed:10666308]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Irodova NL, Krasnikova TL, Masenko VP, Kochetov AG, Chazova IE: [Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrenergic receptors]. Ter Arkh. 2002;74(8):30-4. [PubMed:12360591]
  2. Maebara C, Ohtani H, Sugahara H, Mine K, Kubo C, Sawada Y: Nightmares and panic disorder associated with carvedilol overdose. Ann Pharmacother. 2002 Nov;36(11):1736-40. [PubMed:12398570]
  3. Okajima K, Harada N, Uchiba M, Isobe H: Activation of capsaicin-sensitive sensory neurons by carvedilol, a nonselective beta-blocker, in spontaneous hypertensive rats. J Pharmacol Exp Ther. 2004 May;309(2):684-91. Epub 2004 Feb 5. [PubMed:14764656]
  4. Nichols AJ, Gellai M, Ruffolo RR Jr: Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol. 1991;5(1):25-38. [PubMed:1712335]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Vascular endothelial growth factor receptor binding
Specific Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of...
Gene Name
VEGFA
Uniprot ID
P15692
Uniprot Name
Vascular endothelial growth factor A
Molecular Weight
27042.205 Da
References
  1. de Boer RA, Siebelink HJ, Tio RA, Boomsma F, van Veldhuisen DJ: Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. Eur J Heart Fail. 2001 Jun;3(3):331-3. [PubMed:11378004]
  2. Saijonmaa O, Nyman T, Fyhrquist F: Carvedilol inhibits basal and stimulated ACE production in human endothelial cells. J Cardiovasc Pharmacol. 2004 May;43(5):616-21. [PubMed:15071347]
  3. Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW, Kuan P: Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. J Card Fail. 2005 Mar;11(2):152-9. [PubMed:15732037]
  4. Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H: Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 2005;12(2):409-20. [PubMed:15942707]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Receptor binding
Specific Function
Cardiac hormone which may function as a paracrine antifibrotic factor in the heart. Also plays a key role in cardiovascular homeostasis through natriuresis, diuresis, vasorelaxation, and inhibition...
Gene Name
NPPB
Uniprot ID
P16860
Uniprot Name
Natriuretic peptides B
Molecular Weight
14725.825 Da
References
  1. Ohta Y, Watanabe K, Nakazawa M, Yamamoto T, Ma M, Fuse K, Ito M, Hirono S, Tanabe T, Hanawa H, Kato K, Kodama M, Aizawa Y: Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol. 2000;36 Suppl 2:S19-23. [PubMed:11206715]
  2. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001 Jun 1;37(7):1781-7. [PubMed:11401111]
  3. Konishi H, Nishio S, Tsutamoto T, Minouchi T, Yamaji A: Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: a preliminary study. Int J Clin Pharmacol Ther. 2003 Dec;41(12):578-86. [PubMed:14692707]
  4. Takeda Y, Fukutomi T, Suzuki S, Yamamoto K, Ogata M, Kondo H, Sugiura M, Shigeyama J, Itoh M: Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol. 2004 Aug 15;94(4):448-53. [PubMed:15325927]
  5. Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, Hanna RD, Backes RJ, Mookadam F, Heublein D, Bailey KR, Burnett JC: Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J. 2005 Mar;149(3):541-7. [PubMed:15864245]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Signal transducer activity
Specific Function
Gap junction protein that acts as a regulator of bladder capacity. A gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of ...
Gene Name
GJA1
Uniprot ID
P17302
Uniprot Name
Gap junction alpha-1 protein
Molecular Weight
43008.005 Da
References
  1. Yeh HI, Lee PY, Su CH, Tian TY, Ko YS, Tsai CH: Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. Am J Hypertens. 2006 Feb;19(2):129-35. [PubMed:16448880]
  2. Fan SY, Ke YN, Zeng YJ, Wang Y, Cheng WL, Yang JR: [Effects and the mechanism of carvedilol on gap junctional intercellular communication in rat myocardium]. Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Dec;33(12):1141-5. [PubMed:16563290]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Karle CA, Kreye VA, Thomas D, Rockl K, Kathofer S, Zhang W, Kiehn J: Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res. 2001 Feb 1;49(2):361-70. [PubMed:11164846]
  2. Kawakami K, Nagatomo T, Abe H, Kikuchi K, Takemasa H, Anson BD, Delisle BP, January CT, Nakashima Y: Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. [PubMed:16314852]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Important in cell-cell recognition. Appears to function in leukocyte-endothelial cell adhesion. Interacts with integrin alpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates both adhesion and si...
Gene Name
VCAM1
Uniprot ID
P19320
Uniprot Name
Vascular cell adhesion protein 1
Molecular Weight
81275.43 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen JW, Lin FY, Chen YH, Wu TC, Chen YL, Lin SJ: Carvedilol inhibits tumor necrosis factor-alpha-induced endothelial transcription factor activation, adhesion molecule expression, and adhesiveness to human mononuclear cells. Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2075-81. Epub 2004 Sep 16. [PubMed:15374848]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. [PubMed:15306222]
  2. Van Tassell BW, Rondina MT, Huggins F, Gilbert EM, Munger MA: Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction. Am Heart J. 2008 Aug;156(2):315-21. doi: 10.1016/j.ahj.2008.04.004. Epub 2008 Jun 20. [PubMed:18657662]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. [PubMed:15306222]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. [PubMed:15306222]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. [PubMed:15306222]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Koshimizu TA, Tsujimoto G, Hirasawa A, Kitagawa Y, Tanoue A: Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. [PubMed:15306222]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transmembrane signaling receptor activity
Specific Function
Cell-surface glycoprotein having a role in immunoadhesion. Mediates in the adhesion of blood neutrophils in cytokine-activated endothelium through interaction with PSGL1/SELPLG. May have a role in ...
Gene Name
SELE
Uniprot ID
P16581
Uniprot Name
E-selectin
Molecular Weight
66654.575 Da
References
  1. Chen JW, Lin FY, Chen YH, Wu TC, Chen YL, Lin SJ: Carvedilol inhibits tumor necrosis factor-alpha-induced endothelial transcription factor activation, adhesion molecule expression, and adhesiveness to human mononuclear cells. Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2075-81. Epub 2004 Sep 16. [PubMed:15374848]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Modulator
General Function
Ubiquitin protein ligase binding
Specific Function
Functions as a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transp...
Gene Name
HIF1A
Uniprot ID
Q16665
Uniprot Name
Hypoxia-inducible factor 1-alpha
Molecular Weight
92669.595 Da
References
  1. Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW, Kuan P: Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. J Card Fail. 2005 Mar;11(2):152-9. [PubMed:15732037]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Pdz domain binding
Specific Function
Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentratio...
Gene Name
KCNJ4
Uniprot ID
P48050
Uniprot Name
Inward rectifier potassium channel 4
Molecular Weight
49499.61 Da
References
  1. Ferrer T, Ponce-Balbuena D, Lopez-Izquierdo A, Arechiga-Figueroa IA, de Boer TP, van der Heyden MA, Sanchez-Chapula JA: Carvedilol inhibits Kir2.3 channels by interference with PIP(2)-channel interaction. Eur J Pharmacol. 2011 Oct 1;668(1-2):72-7. doi: 10.1016/j.ejphar.2011.05.067. Epub 2011 Jun 6. [PubMed:21663737]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Xanthine oxidase activity
Specific Function
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Ha...
Gene Name
XDH
Uniprot ID
P47989
Uniprot Name
Xanthine dehydrogenase/oxidase
Molecular Weight
146422.99 Da
References
  1. Yue TL, McKenna PJ, Gu JL, Cheng HY, Ruffolo RE Jr, Feuerstein GZ: Carvedilol, a new vasodilating beta adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc Res. 1994 Mar;28(3):400-6. [PubMed:7909721]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  2. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]
  3. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K: Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999 Dec 1;58(11):1801-6. [PubMed:10571255]
  4. Neuhoff S, Langguth P, Dressler C, Andersson TB, Regardh CG, Spahn-Langguth H: Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther. 2000 Apr;38(4):168-79. [PubMed:10783826]
  5. Hokama N, Hobara N, Sakai M, Kameya H, Ohshiro S, Sakanashi M: Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats. J Pharm Pharmacol. 2002 Jun;54(6):821-5. [PubMed:12078998]
  6. Kakumoto M, Sakaeda T, Takara K, Nakamura T, Kita T, Yagami T, Kobayashi H, Okamura N, Okumura K: Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Cancer Sci. 2003 Jan;94(1):81-6. [PubMed:12708479]
  7. Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. [PubMed:14732961]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13